ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

REGN Regeneron Pharmaceuticals Inc

1,094.99
12.88 (1.19%)
After Hours
Last Updated: 23:07:22
Delayed by 15 minutes
Share Name Share Symbol Market Type
Regeneron Pharmaceuticals Inc NASDAQ:REGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.88 1.19% 1,094.99 1,091.00 1,100.00 1,100.08 1,079.0855 1,087.89 282,365 23:07:22

Statement of Changes in Beneficial Ownership (4)

17/09/2021 9:02pm

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

COLES N ANTHONY
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

9/15/2021
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 9/15/2021  M(1)  6909 A$380.95 7811 D  
Common Stock 9/15/2021  M(1)  5039 A$345.47 12850 D  
Common Stock 9/15/2021  S(1)  300 D$651.36 12550 D  
Common Stock 9/15/2021  S(1)  1101 D$652.95 (2)11449 D  
Common Stock 9/15/2021  S(1)  800 D$653.31 (3)10649 D  
Common Stock 9/15/2021  S(1)  403 D$655.14 (4)10246 D  
Common Stock 9/15/2021  S(1)  1400 D$656.48 (5)8846 D  
Common Stock 9/15/2021  S(1)  835 D$657.53 8011 D  
Common Stock 9/15/2021  S(1)  935 D$658.65 7076 D  
Common Stock 9/15/2021  S(1)  300 D$659.0 6776 D  
Common Stock 9/15/2021  S(1)  448 D$660.78 (6)6328 D  
Common Stock 9/15/2021  S(1)  3344 D$661.56 (7)2984 D  
Common Stock 9/15/2021  S(1)  3 D$662.55 2981 D  
Common Stock 9/15/2021  S(1)  905 D$663.73 (8)2076 D  
Common Stock 9/15/2021  S(1)  1174 D$664.32 (9)902 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy) $345.47 9/15/2021  M (1)    5039   (10)1/27/2027 Common Stock 5039 $0.0 0 D  
Non-Qualified Stock Option (right to buy) $380.95 9/15/2021  M (1)    6909   (10)1/2/2028 Common Stock 6909 $0.0 0 D  

Explanation of Responses:
(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2) Represents volume-weighted average price of sales of 1,101 shares of Company stock on September 15, 2021 at prices ranging from $652.48 to $652.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price.
(3) Represents volume-weighted average price of sales of 800 shares of Company stock on September 15, 2021 at prices ranging from $653.11 to $653.52. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price.
(4) Represents volume-weighted average price of sales of 403 shares of Company stock on September 15, 2021 at prices ranging from $655.14 to $655.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price.
(5) Represents volume-weighted average price of sales of 1,400 shares of Company stock on September 15, 2021 at prices ranging from $656.18 to $656.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price.
(6) Represents volume-weighted average price of sales of 448 shares of Company stock on September 15, 2021 at prices ranging from $660.29 to $660.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price.
(7) Represents volume-weighted average price of sales of 3,344 shares of Company stock on September 15, 2021 at prices ranging from $661.02 to $661.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price.
(8) Represents volume-weighted average price of sales of 905 shares of Company stock on September 15, 2021 at prices ranging from $663.15 to $663.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price.
(9) Represents volume-weighted average price of sales of 1,174 shares of Company stock on September 15, 2021 at prices ranging from $664.00 to $664.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 15, 2021 at each separate price.
(10) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
COLES N ANTHONY
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
X



Signatures
By: Beverly Dubs as attorney-in-fact For: N. Anthony Coles9/17/2021
**Signature of Reporting PersonDate

1 Year Regeneron Pharmaceuticals Chart

1 Year Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart